This week the CDC admitted to withholding data it had collected. According to a report by MSN:
Kristen Nordlund, a spokeswoman for the CDC, said the agency has been slow to release the different streams of data ‘because basically, at the end of the day, it’s not yet ready for prime time.’
She said the agency’s ‘priority when gathering any data is to ensure that it’s accurate and actionable,’ and told The New York Times that they were concerned it might be misinterpreted to show the vaccines were ineffective.
She also said that they were reluctant to publish the data because it represents only 10 percent of the population of the United States – accounting for 33 million people – the same sample size the CDC has used to track influenza for years.
The admission of non-published data has many American scientists and doctors frustrated. Without actual data released from the U.S. government, they are relying on other countries for insights. Insights their own government already has.
Newly Released Information by German Insurer
Andreas Schöfbeck, board member of the German insurance company, BBK, raised concern when he told Die Welt publication:
“The data available to our company gives us reason to believe that there is a very considerable under-recording of suspected cases of vaccination side-effects after they received the [COVID-19] vaccine,” he wrote in his letter.
“If these figures are applied to the year as a whole and to” the entire population of Germany, Schöfbeck estimated, then “probably 2.5-3 million people in Germany been under medical treatment because of vaccination side effects after [COVID-19] vaccination.”
In a country with a population of 83.24 million, and a vaccination rate of 75.2%, these figures coming out of Germany should trigger a warning for countries all over the world. Of the 62.6 million people vaccinated in Germany, if 2.5-3 million sought medical treatment for an adverse event due to a COVID vaccine, that translates into 3.9-4.7% of the people who are fully vaccinated are experiencing these side effects.
40% Increase in Death Rate Among Working Ages in the U.S.
On December 30, 2021, the Indiana Chamber of Commerce and Indiana Hospital Association held a news conference. Insurance company, OneAmerica Indiana’s CEO, Scott Davidson revealed they had seen deaths of people ages 18-64 increase by 40% during the third quarter and continuing into the fourth quarter of 2021 compared to what they were before the COVID pandemic. These deaths were not attributed to COVID. He continued to state that this data was consistent with other agencies. Davidson went on to say that a one in 200-year catastrophe might see a 10% increase. These death rates are considered to be the highest ever seen in the insurance industry.
The increase came after vaccines were made available to the entire adult population.
DoD and VAERS Data In Public View
Recent VAERS numbers show that there have been 1,134,982 reports of adverse events to the COVID vaccines in the U.S. VAERS data is generally considered underreported. It is estimated that 1-13% of the adverse events actually get reported based upon a study done by Harvard. This database is one of nearly a dozen used within the United States.
During a January 24, 2022, round table discussion hosted by Senator Ron Johnson (R-WI), doctors, scientist, nurses and those injured by the COVID vaccines had the opportunity to speak out. During that meeting, information brought forward from within the Department of Defense revealed that there were dramatic increases in several medical conditions following COVID vaccinations among military personnel.
Senator Johnson directed the Secretary of the Department of Defense to respond to his inquiries regarding these increases.
Pfizer and FDA Also Playing Hide and Seek and Withholding Data
Two weeks ago, the FDA announced they were cancelling the VRBPAC meeting to assess the data for Pfizer’s vaccine for infants and toddlers due to fluctuating data. This comes after the reports in December that the Pfizer vaccine had failed to produce the hoped-for immune response data among 2-4-year-olds and a third shot would be added to the regimen. The process of this submission and the data had come under scrutiny well before the announced cancellation of the meeting.
Also at the beginning of February, it was noted that Pfizer added verbiage and raised flags in their fourth quarter earnings releases that “unfavorable pre-clinical, clinical or safety data” may impact business. This was delivered during the February 8th, earning conference call held with investors. This new update came out just after the FDA requested a judge to delay of the release of the data used to approve the vaccines. The request for the data was initiated by a FOIA request. Initially, the FDA had requested 55 years, then upped it to 75 to release the data they had reviewed within 108 days to approve the vaccine. Pfizer also tried to jump into that case requesting the judge to halt the release. The judge denied both requests and the data are to be released, 55,000 pages at a time, throughout this year.
Pfizer isn’t alone, it appears as though there have been recent struggles for competitor, Moderna, recently as well.